• • Company Profile
  • Executive Management
  • Board of Directors
  • Scientific Advisory Board
  • NexMed USA
  • TOTECT
• • NexACT®
  • DDAIP.HCl Properties
  • DDAIP.HCl Molecular Interactions
  • DDAIP: Mechanism of Action
  • NexACT® Diagram
  • Publications
• • Sexual Dysfunction
  • Oncology
  • Autoimmune/Anti-Inflammatory/Pain
  • Anti-Infectives & Cosmeceuticals
  • Metabolic Diseases
  • TOTECT
• • Stock Quotation
  • Interactive Chart
  • Fact Sheet
  • SEC Filings
  • SEC Filings - XBRL Content
  • Corporate Governance
  • Corporate Presentation
  • Social Media
• • Media & Events
  • Press Releases

Home | Search

Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT^® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes.

Revenues and growth are driven from out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide. In addition, the Company is seeking to monetize its existing product pipeline, including its first product, Vitaros^®, approved in Canada for the treatment of erectile dysfunction, which is currently expected to be available on the Canadian market by the second half of 2011 and compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.

For further information on Apricus Bio, visit www.apricusbio.com and for information on its subsidiaries please visit www.nexmedusa.com.